Norris Medicines Ltd

Norris Medicines Q1 2025: Revenue Doubles, Losses Persist 📊

- Revenue from operations: ₹145.66L (vs ₹72.49L same quarter last year)

- Total income (net): ₹148.04L

- Loss before tax: ₹31.04L

- Loss after tax: ₹31.04L

- No exceptional/extraordinary items

- Single business segment (no segmental reporting)

- Results reviewed by Audit Committee, approved by Board

- Prepared under Ind AS & SEBI regulations